Literature DB >> 33179212

In vitro Inhibition of Clinical Isolates of Otitis Media Pathogens by the Probiotic Streptococcus salivarius BLIS K12.

Tzu Yu Chen1, John D F Hale2, John R Tagg2, Rohit Jain2, Abigail L Voss2, Nikki Mills3, Emma J Best4, Duncan S Stevenson5,6, Philip A Bird5,6, Tony Walls5,7.   

Abstract

Otitis media is a common childhood infection, frequently requiring antibiotics. With high rates of antibiotic prescribing and increasing antibiotic resistance, new strategies in otitis media prevention and treatment are needed. The aim of this study was to assess the in vitro inhibitory activity Streptococcus salivarius BLIS K12 against otitis media pathogens. Efficacy of the bacteriocin activity of S. salivarius BLIS K12 against the otitis media isolates was assessed using the deferred antagonism test. Overall, 48% of pathogenic isolates exhibited some growth inhibition by S. salivarius BLIS K12. S. salivarius BLIS K12 can inhibit the in vitro growth of the most common pathogens.

Entities:  

Keywords:  In vitro inhibition; Otitis media; Otitis media pathogens; Probiotics; Recurrent otitis media; S. salivarius BLIS K12

Mesh：

Year:  2020        PMID： 33179212     DOI： 10.1007/s12602-020-09719-7

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN： 1867-1306            Impact factor:   4.609


  8 in total

Review 1.  Probiotics and otitis media in children.

Authors:  Leena Niittynen; Anne Pitkäranta; Riitta Korpela
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2012-02-02       Impact factor: 1.675

2.  Otitis media with effusion: the role of Alloiococcus otitidis.

Authors:  A P Fraise; A L Pahor; A J Beswick
Journal:  Ann Med       Date:  2001-02       Impact factor: 4.709

3.  Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens.

Authors:  Maria Santagati; Marina Scillato; Francesco Patanè; Caterina Aiello; Stefania Stefani
Journal:  FEMS Immunol Med Microbiol       Date:  2012-02-03

4.  Proteinase-related broad-spectrum inhibitory activity among group-A streptococci.

Authors:  W L Hynes; J R Tagg
Journal:  J Med Microbiol       Date:  1986-11       Impact factor: 2.472

Review 5.  The mechanism of action of probiotics.

Authors:  Monica Boirivant; Warren Strober
Journal:  Curr Opin Gastroenterol       Date:  2007-11       Impact factor: 3.287

6.  Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media?

Authors:  Tony Walls; Dan Power; John Tagg
Journal:  J Med Microbiol       Date:  2003-09       Impact factor: 2.472

7.  The Impact of Childhood Acute Otitis Media on Parental Quality of Life in a Prospective Observational Cohort Study.

Authors:  Katsiaryna Holl; Mats Rosenlund; Carlo Giaquinto; Sven-Arne Silfverdal; Alfonso Carmona; James Larcombe; José Garcia-Sicilia; Ahmet Fuat; Maria Eulalia Muñoz; María Luisa Arroba; Brigitte Sloesen; Jens Vollmar; Jean-Yves Pirçon; Johannes G Liese
Journal:  Clin Drug Investig       Date:  2015-10       Impact factor: 2.859

8.  What is behind the ear drum? The microbiology of otitis media and the nasopharyngeal flora in children in the era of pneumococcal vaccination.

Authors:  Nikki Mills; Emma J Best; David Murdoch; Melanie Souter; Michel Neeff; Trevor Anderson; Lesley Salkeld; Zahoor Ahmad; Murali Mahadevan; Colin Barber; Colin Brown; Cameron Walker; Tony Walls
Journal:  J Paediatr Child Health       Date:  2014-09-01       Impact factor: 1.954
  8 in total
  2 in total

1.  Antimicrobial and Antibiofilm Activity of the Probiotic Strain Streptococcus salivarius K12 against Oral Potential Pathogens.

Authors:  Andrea Stašková; Miriam Sondorová; Radomíra Nemcová; Jana Kačírová; Marián Maďar
Journal:  Antibiotics (Basel)       Date:  2021-06-29

2.  A New Approach to Harness Probiotics Against Common Bacterial Skin Pathogens: Towards Living Antimicrobials.

Authors:  Ghazi Khalfallah; Rita Gartzen; Martin Möller; Elisabeth Heine; Rudolf Lütticken
Journal:  Probiotics Antimicrob Proteins       Date:  2021-04-15       Impact factor: 4.609
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.